Search Details

Word: staking (lookup in dictionary) (lookup stats)
Dates: all
Sort By: most recent first (reverse)


Usage:

...arrest, though, Coffee County police learned that the warrant in the neighboring town had been previously recalled. Herring argued that the drug and weapon charges should be inadmissable because the arrest was unlawful. The district court and appeals court denied his request to suppress the evidence. What's at Stake: The pertinent issue in Herring's case is whether evidence should be the excluded if it is obtained during an arrest precipitated by what seems to be correct information given by another law enforcement agency, but in fact is erroneous. In hearing this case, the Supreme Court will revisit...

Author: /time Magazine | Title: The Supreme Court's 2008 Docket | 10/6/2008 | See Source »

...obstacles still lie ahead for RNAi-based drugs, not least of which is how to best deliver them to patients. To solve that question, Roche turned to the outside. Last year Roche bought a 5% stake in Alnylam, a biotech start-up based in Cambridge, Mass., that's a leader in understanding RNAi...

Author: /time Magazine | Title: Roche's Rush | 10/2/2008 | See Source »

When the Alnylam deal was announced in July 2007, Schwan quipped that it could become Roche's "second Genentech." In his wildest dreams. With a market cap of $95 billion, Genentech--of which Roche has owned a 55% majority stake since 1990--has produced some of the most cutting-edge best sellers on the pharmaceutical market today. Its pipeline remains one of the industry's most promising. In the past, Roche always applied a light touch to this golden goose, but this summer it became too tempting for Schwan. On July 21, in what will probably amount to a hostile...

Author: /time Magazine | Title: Roche's Rush | 10/2/2008 | See Source »

British forecaster EvaluatePharma says Roche is on track to take over as Big Pharma's top dog by 2014, up from No. 5 today. But it won't get there without a fight. Crosstown rival Novartis is also revamping how it does R&D and holds a 13% stake in Alnylam. U.K. concern GlaxoSmithKline already underwent its own re-engineering, and the results are evident. In 2000 its pipeline had two major prospects; now, stocked with 34 late-phase drugs on the horizon, it appears to be one of the industry's healthiest...

Author: /time Magazine | Title: Roche's Rush | 10/2/2008 | See Source »

...Obama and you realize he took down a machine without raising his voice. And you look at McCain and he's been the victim of dirty playing in the past. But I also think that in a brute contest in a 50-50 nation with so much power at stake, I have felt a lot of concern that things would devolve into the low, and of course they have...

Author: /time Magazine | Title: Peggy Noonan | 9/30/2008 | See Source »

Previous | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | 100 | 101 | Next